## Note
nid: 1541800160363
model: AnKingOverhaul
tags: #AK_Original_Decks::Step_2::Cheesy_Dorian_(M3), #AK_Step1_v11::#OME_banner, #AK_Step1_v11::#OME_banner::Clinical::12_Psychiatry::12_Peds_Neurodevelopmental, #AK_Step1_v11::#Physeo::09_Pharm::13_Psychiatric::15_Typical_Antipsychotics, #AK_Step1_v11::#Physeo::09_Pharm::13_Psychiatric::16_Atypical_Antipsychotics, #AK_Step1_v11::#Pixorize::03_Pharm::04_Sympathomimetics&lytics::Clonidine_(and_Guanfacine), #AK_Step2_v11::!Shelf::#Cards_AnKing_Did::4fm, #AK_Step2_v11::!Shelf::FM::no_dupes, #AK_Step2_v11::!Shelf::FM::no_dupes::only_step2, #AK_Step2_v11::#OME::12_Psychiatry::12_Peds_Neurodevelopmental, #AK_Step2_v11::#Resources_by_rotation::Psych::emma, #AK_Step2_v11::#Subjects::Psychiatry::12_Childhood_&_Early_Onset_Disorders::Tourettes, #AK_Step2_v11::#Subjects::Psychiatry::12_Childhood_&_Early_Onset_Disorders::Tourettes::Management, #AK_Step2_v11::$AnKingUpdates::$Errata::v11, #AK_Step2_v11::Original_decks::Dorian::fam::amboss, #AK_Step2_v11::Original_decks::Dorian::psych::emma
markdown: false

### Text
<div>
  First line treatment of <b>Tourette's syndrome</b> is {{c1::VMAT2
  inhibitors > atypical antipsychotics}}
</div>

### Extra
<i>UWorld confirms that dopamine modulators such as VMAT2
inhibitors (tetrabenazine) and</i> <i>atypical</i>
<i>antipsychotics are best practice. When choosing between the two,
VMAT2 inhibitors are preferred due to the lower side effect
profile</i> <i>others: <b>guanfacine</b>, <b>clonidine</b></i>
<div>
  <div><img src="paste-31039728648195_1475688242543.jpg" class=
  "resizer"></div>
  <div><img src="paste-595565935067606.jpg" class=
  "resizer"><img src="paste-583346753110524.jpg" class=
  "resizer"></div>
</div>

### Lecture Notes


### Missed Questions


### Pathoma


### Boards and Beyond


### First Aid


### Sketchy


### Pixorize


### Physeo


### OME
<div class="ome-widget">
  <a href=
  "https://onlinemeded.org/spa/psychiatry/peds-neurodevelopmental/acquire?ref=anki">
  <img src="_OME_AnkiFlashcards_Lesson_4.png"></a>
</div>

### Additional Resources


### One by one

